DaVita Inc $ 119.59 0.27 (0.23%)
Warning! GuruFocus has detected 1 Severe warning sign with DVA. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for DVA (DaVita Inc) from 1995 to Jan 23 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. DaVita stock (DVA) PE ratio as of Jan 23 2021 is 17.94. More Details
DaVita PE Ratio (TTM) Historical Data
View and export this data going back to 1995. Start your Free Trial
DaVita PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NYSE:UHS NYSE:CHE NYSE:EHC NAS:AMED NAS:LHCG NAS:ACHC NYSE:THC NAS:OPCH NAS:ENSG NYSE:SEM NYSE:HCA XTER:FRE XTER:FME SZSE:300015 XKLS:5225 BKK:BDMS ASX:RHC ASX:SHL XPAR:ORP BSP:HAPV3
Address 2000 16th Street, Denver, CO, USA, 80202
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates about 3,000 facilities worldwide, mostly in the U.S., and treats over 235,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.